Work

Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis

Year: 2017

Type: article

Source: International Journal of Hematology

DOI: 10.1007/s12185-017-2332-z

Authors: Keita Kirito, Shinichiro Okamoto, Kohshi Ohishi, Tetsuzo Tauchi, Hiroshi Handa, Shigeki Saito, Katsuto Takenaka, Kazuya Shimoda, Kenji Oritani, Koichi Akashi, Hikaru Okada, Taro Amagasaki, Kazuyuki Suzuki, Toshio Yonezu, Norio Komatsu

Institutions: University of Yamanashi Hospital, University of Yamanashi, Keio University Hospital, Mie University Hospital, Tokyo Medical University, Gunma University Hospital, Nagoya University Hospital, Japanese Red Cross Nagoya Daini Hospital, Kyushu University, Kyushu University Hospital, University of Miyazaki, The University of Osaka, Novartis (Japan), Juntendo University

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Novartis Pharma, Japan Society for the Promotion of Science, Novartis Japan

Awards: Clarification of the pathogenesis of myeloproliferative neoplasms based on the identification of genetic factors in familial cases, Analysis of regulation of signals by STAP adaptor protein in immune system and tumorigenesis, Role of glucose metabolism in development of myelofibrosis, Myeloproliferative neoplasms research for drug discovery focusing on CALR mutation and fibrocyte

OpenAlex ID: W2761522391

FWCI: 0.669

Cites: 24

Cited by: 7

Related to: 10